Maravai LifeSciences Holdings, Inc. (MRVI) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Maravai LifeSciences Holdings, Inc. (MRVI) closed at USD 6.55 on 2026-10-14, a change of +102.8 % over the past year, with a market capitalization of USD 2.62B.

Maravai LifeSciences Holdings, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Maravai LifeSciences Holdings, Inc. key figures

Previous close

USD 6.55 (2026-10-14)

1-year change

+102.8 %

Market cap

USD 2.62B

Enterprise value

USD 1.35B

P/E ratio (trailing)

-12.19

P/E ratio (forward)

-70.24

EPS (trailing)

-0.58

EPS (forward)

-0.10

PEG ratio

n/a

Price to book

5.15

Revenue growth

8.5 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

5.22

Employees

415

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Maravai LifeSciences Holdings, Inc.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Maravai LifeSciences Holdings, Inc. and compare it with other stocks.